Chronic Anergic-anhedonic Depression Open Trial

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06110507

Acronym

CADOT

Enrollment

Registered

2023-10-31

Start date

2023-04-01

Completion date

2024-03-22

Last updated

2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Treatment-Resistant

Keywords

Depressive Disorder, Treatment-Resistant, Anergic-anhednic, TRD, TRAD, MAOI, dopamine D2 receptor agonists, D2RAG, dopamine-sensitive

Brief summary

A form of depression called 'dopamine-sensitive anergic-anhedonic syndrome is usually resistant to standard therapies (TRAD). On the other hand, they respond to dopaminergic approaches for which recommendations have been developed: DATA ('Dopaminergic Antidepressant Therapy Algorithm'). These are two stages starting with non-selective monoamineoxidase inhibitors (MAOI) or dopamine D2 receptor agonists (D2RAG) in 'monotherapy' (DATA1) and proposing to combine them in the event of a partial response (DATA2). The effectiveness of this approach in the management of TRAD has not yet been evaluated in routine care. The aim of this study is to evaluate the feasibility and effectiveness in routine care of the DATA recommendations in the management of TRAD presenting to a specialized consultation for resistant depression (short and long-term results).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major patient (≥18 years old) * Man or woman * Patient covered for consultation at the Expert Resistant Depression Center of Alsace (CEDRA) (CHU-Strasbourg branch) for TRAD between 01 January 2013 and 31 March 2023 * Patient not opposing to the reuse of their data for the purposes of this research

Exclusion criteria

* Patient having expressed opposition to participating in the study * Patient under judicial protection * Patient under guardianship or curatorship

Design outcomes

Primary

Measure	Time frame
Proportion of patients in remission; Remission time; Survival curves for remissions and responses	3 months after the patient was taken care of at the Strasbourg University Hospital

Countries

France

Contacts

Primary ContactJack FOUCHER, MD, PhD

jack.foucher@chru-strasbourg.fr33 3 88 11 69 21

Outcome results